Journal of Medicinal Chemistry · 2014 · 14 citations · 28 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular VirologyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyEnzyme InhibitionPotency OptimizationViral HepatitisAntiviral Drug DesignAntiviral Drug MechanismsAntiviral Structure-activity RelationshipsAntiviral TherapeuticsRelative Oral BioavailabilitySmall-molecule Library DesignTherapeutic Index Determination
A series of next in class small-molecule hepatitis C virus (HCV) NS5A inhibitors with picomolar potency containing 2-pyrrolidin-2-yl-5-{4-[4-(2-pyrrolidin-2-yl-1H-imidazol-5-yl)buta-1,3-diynyl]phenyl}-1H-imidazole cores was designed based on the SAR studies available for the reported NS5A inhibitors. Compound 13a (AV4025), with (S,S,S,S)-stereochemistry (EC50 = 3.4 ± 0.2 pM, HCV replicon genotype 1b), was dramatically more active than were the compounds with two (S)- and two (R)-chiral centers. Human serum did not significantly reduce the antiviral activity (<4-fold). Relatively favorable pharmacokinetic features and good oral bioavailability were observed during animal studies. Compound 13a was well tolerated in rodents (in mice, LD50 = 2326 mg/kg or higher), providing a relatively high therapeutic index. During safety, pharmacology and subchronic toxicity studies in rats and dogs, it was not associated with any significant pathological or clinical findings. This compound is currently being evaluated in phase I/II clinical trials for the treatment of HCV infection.
28
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao, Richard E. Nettles, Makonen Belema et al. · Nature · 2010 · 937 citations · Full text